Skip to main
  1. Stocks
  2. Charles River Laboratories
  3. Forecast
CRL

CRL Stock Forecast & Price Target

CRL Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 38%
Buy 46%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Charles River is supported by a strengthening demand backdrop, highlighted by a solid Q3 beat and raise and a 5th consecutive quarter of improving leading indicators, including a 1.09x B2B in DSA that supports expectations for MSD growth in 2027. Its positive outlook also rests on margin expansion levers from pricing power, cost reductions, and divestitures, with management pointing to 5%-7% organic growth and more meaningful improvement in operating margins as pricing from RFPs flows through in 2H27. Manufacturing adds further support, as CRL lifted expectations to MSD organic growth with a higher-margin, post-CDMO portfolio, while NAMs and AI appear more complementary than disruptive, expanding CRL’s role in preclinical and bioanalysis workflows.

Bears say

Charles River is vulnerable to weaker biopharma demand for pre-clinical safety and IND-enabling studies, which could leave growth across RMS, DSA, and Manufacturing below the recovery thesis and pressure operating leverage. The outlook is also burdened by execution risk in the K.F. (Cambodia) vertical integration, where the expected $16M in 2026 and $39M in 2027 EPS accretion and 120 bps of margin uplift could be reduced by cost inflation, supply-chain issues, or lower NHP utilization. In addition, accelerating FDA acceptance of organ-on-chip, organoid, and in silico methods could erode traditional animal-study volumes, especially in DSA, where CRL has only about $120M of NAMs revenue and minimal safety exposure.

CRL has been analyzed by 13 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 46% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Charles River Laboratories and is not a guaranteed prediction by Public.com or investment advice.

CRL Analyst Forecast & Price Prediction

Get the latest CRL stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CRL

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Charles River Laboratories (CRL) Forecast

Analysts have given CRL a Buy based on their latest research and market trends.

According to 13 analysts, CRL has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $327.85, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $327.85, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Charles River Laboratories (CRL)


CRL Analyst Forecast & Price Prediction

Get the latest CRL stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CRL

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CRL stock data and trends